Table 1.
Pre-treatment mean DCE, volumes and clinical parameters in 83 SCC sites (primary plus nodal) correlated with SF or SC at the same site, based on a minimum of 2 year clinical follow-up.
Table 2.
Pre-treatment mean DCE parameters in 43 primary sites and 40 nodal sites correlated with SF or SC at the same SCC site, based on a minimum of 2 year clinical follow-up.
Fig 1.
MRI, AUGC and kep maps in the axial plane from a 70 year old male with oropharyngeal carcinoma and SC 46.7 months after chemoradiotherapy.
(a) Pre-treatment T1-weighted post contrast image of the SCC, (b) Pre-treatment AUGC map (mean AUGC = 2.36), (c) Pre-treatment kep map (mean kep = 1.62); (d) Post-treatment T1-weighted post contrast image of the SC residual mass, (e) Post-treatment AUGC map (mean AUGC = 0.96), (f) Post-treatment kep map (mean kep = 0.09).
Fig 2.
MRI, AUGC and kep maps in the axial plane from an 85 year old male with oral cavity carcinoma with SF 3.6 months after chemoradiotherapy.
(a) Pre-treatment T1-weighted post contrast image of the SCC, (b) Pre-treatment AUGC map (mean AUGC = 3.07), (c) Pre-treatment kep map (mean kep = 0.88); (d) Post-treatment T1-weighted post contrast image of the residual mass with SF, (e) Post-treatment AUGC map AUGC (mean AUGC = 3.72), (f) Post-treatment kep map (mean kep = 0.63).
Fig 3.
Box plots showing pre-treatment AUGC in 33 SCC sites and post-treatment AUGC in SC and SF residual masses.
SC residual masses showed significantly lower AUGC than SF residual masses.
Fig 4.
Receiver-operating characteristics curve. Receiver operating characteristic curve for the % change in AUGC of a post-treatment residual mass, for distinguishing between SC residual masses and SF residual masses.
Area under the curve of 0.77 when using a > 19.78% increase in AUGC to predict SF.
Table 3.
Post treatment residual mass in 33 SCC sites (primary plus nodal): mean DCE and volumes (and % change when compared to pre-treatment), and clinical parameters for SC residual masses and SF residual masses, based on a minimum of 2 year clinical follow-up.
Table 4.
Diagnostic performance of % change in AUGC to identify residual masses with SF.
Table 5.
Post-treatment residual mass in 19 primary sites and 14 nodal sites; mean DCE parameters (and % change when compared to pre-treatment) for SC residual masses and SF residual masses, based on a minimum of 2 year clinical follow-up.